Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis

被引:529
|
作者
Chen, Zhu [1 ]
Bozec, Aline [2 ,3 ]
Ramming, Andreas [2 ,3 ]
Schett, Georg [2 ,3 ]
机构
[1] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Dept Rheumatol & Immunol, Hefei, Anhui, Peoples R China
[2] Friedrich Alexander Univ, Dept Internal Med 3, Erlangen, Germany
[3] Univ Klinikum Erlangen, Erlangen, Germany
基金
中国国家自然科学基金;
关键词
COLLAGEN-INDUCED ARTHRITIS; SCHISTOSOMA-MANSONI INFECTION; SYNOVIAL-FLUID MACROPHAGES; PARASITIC WORM PRODUCT; INNATE LYMPHOID-CELLS; INTERLEUKIN-10; TREATMENT; TNF-ALPHA; T-CELLS; IMMUNOREGULATORY ROLE; BONE DESTRUCTION;
D O I
10.1038/s41584-018-0109-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by a failure of spontaneous resolution of inflammation. Although the pro-inflammatory cytokines and mediators that trigger RA have been the focus of intense investigations, the regulatory and anti-inflammatory cytokines responsible for the suppression and resolution of disease in a context-dependent manner have been less well characterized. However, knowledge of the pathways that control the suppression and resolution of inflammation in RA is clinically relevant and conceptually important for understanding the pathophysiology of the disease and for the development of treatments that enable long-term remission. Cytokine-mediated processes such as the activation of T helper 2 cells by IL-4 and IL-13, the resolution of inflammation by IL-9, IL-5-induced eosinophil expansion, IL-33-mediated macrophage polarization, the production of IL-10 by regulatory B cells and IL-27-mediated suppression of lymphoid follicle formation are all involved in governing the regulation and resolution of inflammation in RA. By better understanding these immune-regulatory signalling pathways, new therapeutic strategies for RA can be envisioned that aim to balance and resolve, rather than suppress, inflammation.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 50 条
  • [31] CLINICAL MEASUREMENT OF ANTI-INFLAMMATORY EFFECTS OF SALICYLATES IN RHEUMATOID ARTHRITIS
    BOARDMAN, PL
    HART, FD
    BMJ-BRITISH MEDICAL JOURNAL, 1967, 4 (5574): : 264 - +
  • [32] Anti-inflammatory and immunoregulatory effects of pinolenic acid in rheumatoid arthritis
    Takala, Rabaa
    Ramji, Dipak P.
    Andrews, Robert
    Zhou, You
    Burston, James
    Choy, Ernest
    RHEUMATOLOGY, 2022, 61 (03) : 992 - 1004
  • [33] The Endocannabinoid System: a new anti-inflammatory target in rheumatoid arthritis
    Tan, Kyle Boon Chin
    Murray, Elaine K.
    Watterson, Steven
    Alexander, Denis
    Linden, James
    Gibson, David S.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [35] Proinflammatory and Anti-Inflammatory Cytokines in Gingival Crevicular Fluid and Serum of Patients With Rheumatoid Arthritis and Patients With Chronic Periodontitis
    Cetinkaya, Burcu
    Guzeldemir, Esra
    Ogus, Ersin
    Bulut, Sule
    JOURNAL OF PERIODONTOLOGY, 2013, 84 (01) : 84 - 93
  • [36] ANTI-INFLAMMATORY AND IMMUNOLOGIC ACTIONS OF PINOLENIC ACID IN RHEUMATOID ARTHRITIS
    Takala, Rabaa
    Ramji, Dipak
    Choy, Ernest
    RHEUMATOLOGY, 2020, 59
  • [37] ASPIRIN AND NEWER ANTI-INFLAMMATORY AGENTS IN RHEUMATOID-ARTHRITIS
    TURNER, R
    AMERICAN FAMILY PHYSICIAN, 1977, 16 (01) : 111 - 115
  • [38] ITACONATE - A GLUCOSE METABOLITE WITH ANTI-INFLAMMATORY PROPERTIES IN RHEUMATOID ARTHRITIS
    Andersen, B.
    Olagnier, D.
    Hetland, M. L.
    Ostergaard, M.
    Horslev-Petersen, K.
    Junker, P.
    Stengaard-Pedersen, K.
    Deleuran, B.
    Nielsen, M. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 833 - 833
  • [39] COMPARISON OF ANTI-INFLAMMATORY DRUGS WITH GLUCOCORTICOIDS IN TREATMENT OF RHEUMATOID ARTHRITIS
    Coskun, B. N.
    Ulutas, F.
    Ermurat, S.
    Dalkilic, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1196 - 1196
  • [40] EFFICACY IN RHEUMATOID-ARTHRITIS WITH A NOVEL ANTI-INFLAMMATORY DRUG
    ADAIR, SF
    SINGLETON, C
    REID, R
    SCHWARTZMAN, M
    GAUSE, D
    FURST, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (02) : 176 - 176